Pfizer Inc PFE.N reported quarterly adjusted earnings of 63 cents per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of 10 cents. The mean expectation of fifteen analysts for the quarter was for earnings of 47 cents per share. Wall Street expected results to range from 34 cents to 66 cents per share.
Revenue rose 24.7% to $17.76 billion from a year ago; analysts expected $17.36 billion.
Pfizer Inc's reported EPS for the quarter was 7 cents.
The company reported quarterly net income of $410 million.
Pfizer Inc shares had fallen by 1.2% this quarter.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 1.3% in the last three months.
In the last 30 days, two analysts negatively revised earnings estimates
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy," 13 "hold" and 1 "sell" or "strong sell."
The average consensus recommendation for the pharmaceuticals peer group is also "buy"
Wall Street's median 12-month price target for Pfizer Inc is $31.00
This summary was machine generated from LSEG data February 4 at 02:31 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Dec. 31 2024 | 0.47 | 0.63 | Beat |
Sep. 30 2024 | 0.62 | 1.06 | Beat |
Jun. 30 2024 | 0.46 | 0.60 | Beat |
Mar. 31 2024 | 0.52 | 0.82 | Beat |